Angiotensin II receptor blockade in diabetic nephropathy

Danish Medical Bulletin

Volumn 51, Issue 3, 2004, Pages 274-294

  Andersen, Steen ^a,b  

^a STENO DIABETES CENTER   (Denmark)

^b NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLUCOSE; GROWTH FACTOR; IMMUNOGLOBULIN; IRBESARTAN; LISINOPRIL; LOSARTAN; NEPHRIN; NISOLDIPINE; PLACEBO; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RENIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALLELE; AUTOCRINE EFFECT; BLOOD PRESSURE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HOMOZYGOSITY; HUMAN; HYPERTENSION; INDIVIDUALIZATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD FLOW; MEDICAL DECISION MAKING; MESANGIUM CELL; META ANALYSIS; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PHARMACOGENETICS; PODOCYTE; PROGNOSIS; PROTEIN EXPRESSION; PROTEINURIA; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY; KIDNEY GLOMERULUS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 4944250828     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (255)

1. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young Type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk-factors. Diabetologia 1987;30:144-148.
2. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J 1987;294:1651-1654.
3. Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In: Brenner BM, Levine S, editors. The Kidney. Philadelphia: WB Saunders, 2000:1731-1773.
4. Rossing P, Rossing K, Jacobsen P, Parving H-H. Unchanged incidence of diabetic nephropathy in IDDM patients. Diab 1995;44:739-743.
5. Ballard DJ, Humphrey LL, Melton III LJ, Frohnert PP, Chu C-P, O'Fallon WM et al. Epidemiology of persistent proteinuria in Type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diab 1988;37:405-412.
6. Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand J Clin Lab Invest 1976;36:383-388.
7. Parving H-H, Smidt UM, Friisberg B, Bonnevie-Nielsen V, Andersen AR. A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia 1981;20:457-461.
8. Viberti GC, Bilous RW, Mackintosh D, Keen H. Monitoring glomerular function in diabetic nephropathy. Am J Med 1983;74:256-264.
9. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int 2001;59(2):702-709.
10. Wolf G, Ziyadeh FN. The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 1997; 29(1):153-163.
11. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2002;25(Suppl. 1):s71-s73.
12. Lewis E, Hunsicker L, Bain R, Rhode R. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
13. Rossing P, Hommel E, Smidt UM, Parving H-H. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 1994;45(Suppl. 45):S145-S149.
14. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 1994;45(Suppl. 45):S174-S178.
15. Rossing P. Promotion, prediction, and prevention of progression in diabetic nephropathy. Diabetic Med 1998;15(11):900-919.
16. Scandling JD, Myers BD. Glomerular size-selectivity and microalbuminuria in early diabetic glomerular disease. Kidney Int 1992;41:840-846.
17. Morelli E, Loon N, Meyer TW, Peters W, Myers BD. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diab 1990;39:76-82.
18. Parving H-H, Andersen AR, Smidt UM, Svendsen PAa. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;i:1175-1179.
19. Mogensen CE, Chachati A, Christensen CK, Close CF, Deckert T, Hommel E et al. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest 1985;9:85-95.
20. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000;36(3):449-467.
21. Kennefick TM, Anderson S. Role of angiotensin II in diabetic nephropathy. Semin Nephrol 1997;17(5):441-447.
22. Navar LG, Harrison-Bernard LM, Imig JD, Wang CT, Cervenka L, Mitchell KD. Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J Am Soc Nephrol 1999;10(Suppl. 12):S266-S272.
23. Becker BN, Yasuda T, Kondo S, Vaikunth S, Homma T, Harris RC. Mechanical stretch/relaxation stimulates a cellular renin-angiotensin system in cultured rat mesangial cells. Exp Nephrol 1998;6(1):57-66.
24. Lai KN, Leung JC, Lai KB, To WY, Yeung VT, Lai FM. Gene expression of the renin-angiotensin system in human kidney. J Hypertens 1998; 16(1):91-102.
25. Burns KD, Homma T, Harris RC. The intrarenal renin-angiotensin system. Semin Nephrol 1993;13(1):13-30.
26. Chen M, Harris MP, Rose D, Smart A, He XR, Kretzler M et al. Renin and renin mRNA in proximal tubules of the rat kidney. J Clin Invest 1994;94(1):237-243.
27. Ingelfinger JR, Zuo WM, Fon EA, Ellison KE, Dzau VJ. In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest 1990;85(2):417-423.
28. Harrison-Bernard LM, Navar LG, Ho MM, Vinson GP, el Dahr SS. Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol 1997;273(1 Pt 2): F170-F177.
29. Navar LG, Harrison-Bernard LM, Imig JD, Wang CT, Cervenka L, Mitchell KD. Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J Am Soc Nephrol 1999;10(Suppl. 12):S266-S272.
30. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993;265(4 Pt 2):F477-F486.
31. Jaffa AA, Chai KX, Chao J, Chao L, Mayfield RK. Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney. Kidney Int 1992;41(4):789-795.
32. Zimpelmann J, Kumar D, Levine DZ, Wehbi G, Imig JD, Navar LG et al. Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int 2000;58(6):2320-2330.
33. Ballermann BJ, Skorecki KL, Brenner BM. Reduced glomerular angiotensin II receptor density in early untreated diabetes mellitus in the rat. Am J Physiol 1984;247:F110-F115.
34. Cheng HF, Burns KD, Harris RC. Reduced proximal tubule angiotensin II receptor expression in streptozotocin-induced diabetes mellitus. Kidney Int 1994;46(6):1603-1610.
35. Campbell DJ, Kelly DJ, Wilkinson-Berka JL, Cooper ME, Skinner SL. Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. Kidney Int 1999;56(1):211-221.
36. Vallon V, Wead LM, Blantz RC. Renal hemodynamics and plasma and kidney angiotensin II in established diabetes mellitus in rats: effect of sodium and salt restriction. J Am Soc Nephrol 1995;5(10):1761-1767.
37. Price DA, Porter LE, Gordon M, Fisher ND, De'Oliveira JM, Laffel LM et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999;10(11):2382-2391.
38. Miller JA. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 1999;10(8): 1778-1785.
39. Navar LG, Imig JD, Zou L, Wang CT. Intrarenal production of angiotensin II. Semin Nephrol 1997;17(5):412-422.
40. Blantz RC, Gabbai FB. Effect of angiotensin II on glomerular hemodynamics and ultrafiltration coefficient. Kidney Int Suppl 1987;20: S108-S111.
41. Blantz RC, Konnen KS, Tucker BJ. Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest 1976;57(2):419-434.
42. Myers BD, Deen WM, Brenner BM. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 1975;37(1):101-110.
43. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-1930.
44. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985;76:612-619.
45. Imanishi M, Yoshioka K, Konishi Y, Okumura M, Okada N, Sato T et al. Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Diabetologia 1999;42(8):999-1005.
46. Andersen S, Jacobsen P, Tarnow L, Rossing P, Juhl TR, Parving HH. Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Nephrol Dial Transplant 2003;18(2):293-297.
47. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-b expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-2437.
48. Ray PE, Bruggeman LA, Horikoshi S, Aguilera G, Klotman PE. Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors. Kidney Int 1994; 45:177-184.
49. Weigert C, Brodbeck K, Klopfer K, Haring HU, Schleicher ED. Angiotensin II-induced TGF-beta1 promoter activation. Diabetologia 2002; 45(6):890-898.
50. Yamamoto T, Nakamura R, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor b is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-1818.
51. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease - the case for transforming growth factor-b as a key mediator. Diab 1995; 44:1139-1146.
52. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994;93:536-542.
53. Singh R, Alavi N, Singh AK, Leehey DJ. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diab 1999; 48:2066-2073.
54. Riser BL, Cortes P. Connective tissue growth factor and its regulation: a new element in diabetic glomerulosclerosis. Ren Fail 2001;23(3-4):459-470.
55. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995;25(5):913-917.
56. Simon M, Grone HJ, Johren O, Kullmer J, Plate KH, Risau W et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995;268(2 Pt 2):F240-F250.
57. Hovind P, Tarnow L, Østergaard P, Parving HH. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57(Suppl. 75):S-56-S-61.
58. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331: 1480-1487.
59. Kagami S, Kuhara T, Okada K, Kuroda Y, Border WA, Noble NA. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 1997;51(3):664-671.
60. Rabelink TJ, Bakris GL. The renin-angiotensin system in diabetic nephropathy: the endothelial connection. Miner Electrolyte Metab 1998; 24(6):381-388.
61. Kone BC. Nitric oxide in renal health and disease. Am J Kidney Dis 1997;30(3):311-333.
62. Jaimes EA, Galceran JM, Raij L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998;54(3):775-784.
63. Kohno M, Horio T, Ikeda M, Yokokawa K, Fukui T, Yasunari K et al. Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. Kidney Int 1992;42(4):860-866.
64. Bakris GL, Re RN. Endothelin modulates angiotensin II induced mitogenesis of human mesangial cells. Am J Physiol 1993;264:F937-F942.
65. Desideri G, Ferri C, Bellini C, De Mattia G, Santucci A. Effects of ACE inhibition on spontaneous and insulin-stimulated endothelin-1 secretion: in vitro and in vivo studies. Diab 1997;46(1):81-86.
66. Wolf G. Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease: beyond haemodynamics. Nephrol Dial Transplant 1998;13(5):1131-1142.
67. Siragy HM. AT(1) and AT(2) receptors in the kidney: role in disease and treatment. Am J Kidney Dis 2000;36(3 Suppl. 1):S4-S9.
68. Sharma M, Sharma R, Greene AS, McCarthy ET, Savin VJ. Documentation of angiotensin II receptors in glomerular epithelial cells. Am J Physiol 1998;274(3 Pt 2):F623-F627.
69. Gloy J, Henger A, Fischer KG, Nitschke R. Angiotensin II modulates cellular functions of podocytes. Kidney Int 2002;54:168-170.
70. Yuan BH, Robinette JB, Conger JD. Effect of angiotensin II and norepinephrine on isolated rat afferent and efferent arterioles. Am J Physiol 1990;258(3 Pt 2):F741-F750.
71. Daniels BS. The role of the glomerular epithelial cell in the maintenance of the glomerular filtration barrier. Am J Nephrol 1993;13(5):318-323.
72. Wolf G, Ziyadeh FN, Stahl RA. Angiotensin II stimulates expression of transforming growth factor beta receptor type II in cultured mouse proximal tubular cells. J Mol Med 1999;77(7):556-564.
73. Arima S, Ito S. Angiotensin II type 2 receptors in the kidney: evidence for endothelial-cell-mediated renal vasodilatation. Nephrol Dial Transplant 2000;15(4):448-451.
74. Zimpelmann J, Burns KD. Angiotensin II AT(2) receptors inhibit growth responses in proximal tubule cells. Am J Physiol Renal Physiol 2001;281(2):F300-F308.
75. Siragy HM, Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 1999;33(5):1237-1242.
76. Rizkalla B, Cao Z, Forbes J, Cooper ME. Pivotal role of the AT2 receptor subtype in mediating angiotensin II induced renal VEGF expression. Journal af the American Society of Nephrology 13, 149A. 2002. Ref type: Abstract
77. Cao Z, Bonnet F, Candido R, Nesteroff SP, Burns WC, Kawachi H et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 2002;13(7): 1773-1787.
78. Wehbi GJ, Zimpelmann J, Carey RM, Levine DZ, Burns KD. Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors. Am J Physiol Renal Physiol 2001;280(2):F254-F265.
79. Hollenberg NK, Fisher NDL, Price DA. Pathways for angiotensin II generation in intact human tissue. Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-392.
80. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blokade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601-606.
81. van den Meiracker AH, Man in't Veld AJ, Admiraal PJ, Ritsema van Eck HJ, Boomsma F, Derkx FH et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992;10(8):803-812.
82. Myers BD. Pathophysiology of proteinuria in diabetic glomerular disease. J Hypertens Suppl 1990;8(1):S41-S46.
83. Myers BD, Winetz JA, Chui F, Michaels AS. Mechanisms of proteinuria in diabetic nephropathy: a study of glomerular barrier function. Kidney Int 1982;21:633-641.
84. Tojo A, Endou H. Intrarenal handling of proteins in rats using fractional micropuncture technique. Am J Physiol 1992;263(4 Pt 2):F601-F606.
85. Oken DE, Kirschbaum BB, Landwehr DM. Micropuncture studies of the mechanisms of normal and pathologic albuminuria. Contrib Nephrol 1981;24:1-7.
86. Baldamus CA, Galaske R, Eisenbach GM, Krause HP, Stolte H. Glomerular protein filtration in normal and nephritic rats. A micropuncture study. Contrib Nephrol 1975;1:37-49.
87. Bertolatus JA, Hunsicker LG. Glomerular sieving of anionic and neutral bovine albumins in proteinuric rats. Kidney Int 1985;28(3):467-476.
88. Rennke HG, Patel Y, Venkatachalam MA. Glomerular filtration of proteins: clearance of anionic, neutral, and cationic horseradish peroxidase in the rat. Kidney Int 1978;13(4):278-288.
89. Rennke HG, Venkatachalam MA. Glomerular permeability of macromolecules. Effect of molecular configuration on the fractional clearance of uncharged dextran and neutral horseradish peroxidase in the rat. J Clin Invest 1979;63(4):713-717.
90. Deen WM, Lazzara MJ, Myers BD. Structural determinants of glomerular permeability. Am J Physiol Renal Physiol 2001;281(4):F579-F596.
91. Chang RS, Robertson CR, Deen WM, Brenner BM. Permselectivity of the glomerular capillary wall to macromolecules. I. Theoretical considerations. Biophys J 1975;15(9):861-886.
92. Deen WM, Bridges CR, Brenner BM, Myers BD. Heteroporous model of glomerular size-selectivity: application to normal and nephrotic humans. Am J Physiol 1985;249:F374-F389.
93. Oliver III JD, Anderson S, Troy JL, Brenner BM, Deen WM. Determination of glomerular size-selectivity in the normal rat with Ficoll. J Am Soc Nephrol 1992;3:214-228.
94. Blouch K, Deen WM, Fauvel JP, Bialek J, Derby G, Myers BD. Molecular configuration and glomerular size selectivity in healthy and nephrotic humans. Am J Physiol 1997;273(3 Pt 2):F430-F437.
95. Bohrer MP, Patterson GD, Carroll PJ. Hindered diffusion of dextran and Ficoll in microporous membranes. Macromolecules 2002;17:1170-1173.
96. Bohrer MP, Deen WM, Robertson CR, Troy JL, Brenner BM. Influence of molecular configuration on the passage of macromolecules across the glomerular capillary wall. J Gen Physiol 1979;74(5):583-593.
97. Davidson MG, Deen WM. Hindered diffusion of water-soluble macromolecules in membranes. Macromolecules 2002;21:3474-3481.
98. Galaske RG, Van Liew JB, Feld LG. Filtration and reabsorption of endogenous low-molecular-weight protein in the rat kidney. Kidney Int 1979;16(3):394-403.
99. Tucker BJ, Rasch R, Blantz RC. Glomerular filtration and tubular reabsorption of albumin in preproteinuric and proteinuric diabetic rats. J Clin Invest 1993;92(2):686-694.
100. Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, Battaglia C et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993; 4:40-49.
101. Lapinski R, Perico N, Remuzzi A, Sangalli F, Benigni A, Remuzzi G. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 1996;7(5):653-660.
102. Tomlanovich S, Deen WM, Jones HW, III, Schwartz HC, Myers BD. Functional nature of glomerular injury in progressive diabetic glomerulopathy. Diab 1987;36(5):556-565.
103. Nakamura Y, Myers BD. Charge selectivity of proteinuria in diabetic glomerulopathy. Diab 1988;37:1202-1211.
104. Deckert T, Kofoed-Enevoldsen A, Vidal P, Nørgaard K, Andreasen HB, Feldt-Rasmussen B. Size- and charge selectivity of glomerular filtration in Type 1 (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia 1993;36:244-251.
105. Myers BD, Nelson RG, Tan M, Beck GJ, Bennett PH, Knowler WC et al. Progression of overt nephropathy in non-insulin-dependent diabetes. Kidney Int 1995;47(6):1781-1789.
106. Ala-Houhala I, Pasternack A. Fractional dextran and protein clearances in glomerulonephritis and in diabetic nephropathy. Clin Sci (Lond) 1987;72(3):289-296.
107. Ruggenenti P, Mosconi L, Sangalli F, Casiraghi F, Gambara V, Remuzzi G et al. Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. Kidney Int 1999;55(3):984-994.
108. Deckert T, Feldt-Rasmussen B, Djurup R, Deckert M. Glomerular size and charge selectivity in insulin-dependent diabetes mellitus. Kidney Int 1988;33:100-106.
109. Ghiggeri GM, Candiano G, Delfino G, Queirolo C. Electrical charge of serum and urinary albumin in normal and diabetic humans. Kidney Int 1985;28(2):168-177.
110. di Mario U, Morano S, Cancelli A, Bacci S, Frontoni S, Pietravalle P et al. New parameters to monitor the progression of diabetic nephropathy. Am J Kidney Dis 1989;13(1):45-48.
111. Kverneland A, Feldt-Rasmussen B, Vidal P, Welinder B, Bent-Hansen L, Soegaard U et al. Evidence of changes in renal charge selectivity in patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1986;29(9):634-639.
112. Christensen EI, Carone FA, Rennke HG. Effect of molecular charge on endocytic uptake of ferritin in renal proximal tubule cells. Lab Invest 1981;44(4):351-358.
113. Christensen EI, Rennke HG, Carone FA. Renal tubular uptake of protein: effect of molecular charge. Am J Physiol 1983;244(4):F436-F441.
114. Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD. Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 2000;58(5):2129-2137.
115. Deen WM, Satvat B. Determinants of the glomerular filtration of proteins. Am J Physiol 1981;214:F162-F170.
116. Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J et al. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Kidney Int 2002;62(1):192-198.
117. Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH. Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 2002;17(8):1413-1418.
118. Remuzzi A, Ruggenenti P, Mosconi L, Pata V, Viberti GC, Remuzzi G. Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. J Nephrol 1993;6:36-43.
119. Hansen PM, Mathiesen ER, Kofoed-Enevoldsen A, Deckert T. Possible effect of angiotensin-converting enzyme inhibition on glomerular charge selectivity. Journal of Diabetes and Its Complications 1995 1995; 9:158-162.
120. Plum J, Bunten B, Nemeth R, Grabensee B. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998;9(12):2223-2234.
121. Remuzzi A, Perico N, Sangalli F, Vendramin G, Moriggi M, Ruggenenti P et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 1999;276(3 Pt 2): F457-F466.
122. Daniels BS, Deen WM, Mayer G, Meyer T, Hostetter TH. Glomerular permeability barrier in the rat. Functional assessment by in vitro methods. J Clin Invest 1993;92(2):929-936.
123. Tryggvason K. Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 1999;10(11):2440-2445.
124. Rodewald R, Karnovsky MJ. Porous substructure of the glomerular slit diaphragm in the rat and mouse. J Cell Biol 1974;60(2):423-433.
125. Holthofer H, Ahola H, Solin ML, Wang S, Palmen T, Luimula P et al. Nephrin localizes at the podocyte filtration slit area and is characteristically spliced in the human kidney. Am J Pathol 1999;155(5):1681-1687.
126. Holzman LB, St John PL, Kovari IA, Verma R, Holthofer H, Abrahamson DR. Nephrin localizes to the slit pore of the glomerular epithelial cell. Kidney Int 1999;56(4):1481-1491.
127. Ruotsalainen V, Ljungberg P, Wartiovaara J, Lenkkeri U, Kestila M, Jalanko H et al. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci USA 1999;96(14):7962-7967.
128. Lenkkeri U, Mannikko M, McCready P, Lamerdin J, Gribouval O, Niaudet PM et al. Structure of the gene for congenital nephrotic syndrome of the finnish type (NPHS1) and characterization of mutations. Am J Hum Genet 1999;64(1):51-61.
129. Putaala H, Soininen R, Kilpelainen P, Wartiovaara J, Tryggvason K. The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death. Hum Mol Genet 2001;10(1):1-8.
130. Mifsud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, Cooper ME et al. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001;44(7):878-882.
131. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997;99(2):342-348.
132. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001;44(7):874-877.
133. Benigni A, Tomasoni S, Gagliardini E, Zoja C, Grunkemeyer JA, Kalluri R et al. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 2001;12(5): 941-948.
134. Macconi D, Ghilardi M, Bonassi ME, Mohamed EI, Abbate M, Colombi F et al. Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. J Am Soc Nephrol 2000;11(3):477-489.
135. Joint National Committee on Detection EaToHBP. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157: 2413-2446.
136. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36(3):646-661.
137. de Jong PE, Navis GJ, de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999;354:352-353.
138. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;i:1430-1432.
139. Parving HH, Oxenbøll B, Svendsen PAa, Christiansen JS, Andersen AR. Early detection of patients at risk of developing diabetic nephropathy. Acta Endocrinol 1982;100:550-555.
140. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984;311:89-93.
141. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984;310:356-360.
142. Christensen CK, Mogensen CE. Effect of antihypertensive treatment on progression of incipient diabetic nephropathy. Hypertension 1985; 7(6 Pt 2):II109-II113.
143. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001;134(5):370-379.
144. Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive diabetic patients with microalbuminuria. Br Med J 1991;303:81-87.
145. Marre M, Chatellier G, Leblanc H, Guyenne T-T, Ménard J, Passa Ph. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 1988;297:1092-1095.
146. Viberti GC, Mogensen CE, Groop L, Pauls JF, the European Microalbuminuria Captopril Study Group. Effect of Captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;271:275-279.
147. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 1999;319:24-25.
148. Buter H, Navis G, Dullaart RP, de Zeeuw D, de Jong PE. Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Nephrol Dial Transplant 2001;16(4):771-775.
149. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 1996;156:286-289.
150. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco RG, Strollo G et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21(4):597-603.
151. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998;317:713-720.
152. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl. 2):B54-B64.
153. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica D, Broadstone V et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int 1994;45 (Suppl. 45):S150-S155.
154. Agardh C-D, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. Journal of Human Hypertension 1996;10:185-192.
155. Gæde P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-622.
156. Lacourciere Y, Nadeau A, Poirier L, Tancrede G. Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 1993;21(6 Pt 1):786-794.
157. Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995;8(9):876-883.
158. Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000;57(2):590-600.
159. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345(12):870-878.
160. Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, D'Ambrosio R et al. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double- blind placebo-controlled crossover study. Diabetes Care 2002;25(11):1909-1913.
161. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106(6):672-678.
162. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 1982;285:685-688.
163. Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial effect of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986;293:471-474.
164. Parving HH, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. Br Med J 1988;297:1086-1091.
165. Björck S, Mulec H, Johnsen SAa, Nordén G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992;304:339-343.
166. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000;35(4):695-707.
167. Vanhoutte PM. Endothelium and control of vascular function. Hypertension 1989;13:658-667.
168. Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME. role of angiotensin II and bradykinin in experimental diabetic nephropathy. Diab 1997;46: 1612-1618.
169. Kon V, Fogo A, Ichikawa I, Hellings SE, Bills T. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993;44:545-550.
170. Fenoy F, Scicli G, Carretero O, Roman RJ. Effect of an angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captopril. Hypertension 1991;17:1038-1044.
171. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-1292.
172. Lansang MC, Price DA, Laffel LM, Osei SY, Fisher ND, Erani D et al. Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. Kidney Int 2001;59(4):1432-1438.
173. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45:861-867.
174. Andersen S, Tarnow L, Cambien F. Long-term renoprotective effect of losartan in diabetic nephropathy: interaction with ACE/ID genotype? Diabetes Care 2003;26 (5):1501-1506
175. Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2000;23(12):1725-1730.
176. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-1650.
177. Nielsen FS, Rossing P, Gall M-A, Skøtt P, Smidt UM, Parving HH. Long-term effect of lisinopril and atenolol on kidney function in hypertensive non-insulin-dependent diabetic subjects with diabetic nephropathy. Diab 1997;46:1182-1188.
178. Fogari R, Zoppi A, Corradi L, Mugellini A, Lazzari P, Preti P et al. Longterm effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. Journal of Humamn Hypertension 1999;13:47-53.
179. Walker WG, Hermann J, Anderson J, Zachary J, Russell RP. Blood pressure (BP) control slows decline of glomerular filtration rate (GFR) in hypertensive NIDDM patients. Journal af the American Society of Nephrology 3 (3), 339. 1992 (Abstract).
180. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12):861-869.
181. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-860.
182. Gansevoort RT, de Zeeuw D, de Jong PE. Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition. Kidney Int 1993;44:579-584.
183. Rossing P. Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus. Diabet Med 1998;15(11):900-919.
184. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990;38:384-394.
185. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enelapril maleate in patients with essential hypertension. Hypertension 1995;25: 1345-1350.
186. Hansen HP, Rossing P, Tarnow L, Nielsen FS, Jensen BR, Parving HH. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 1995;47: 1726-1731.
187. Laverman GD, Henning RH, de Jong PE, Navis G, de Zeeuw D. Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 2001;38(6):1381-1384.
188. Kelly DJ, Skinner SL, Gilbert RE, Cox AJ, Cooper ME, Wilkinson-Berka JL. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney Int 2000;57(5):1882-1894.
189. Esmatjes E, Flores L, Inigo P, Lario S, Ruilope LM, Campistol JM. Effect of losartan on TGF-beta 1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 2001;16(Suppl. 1):90-93.
190. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 2002;25(6):1072-1077.
191. Peters H, Border WA, Noble NA. Targeting TGF-overexpression in renal disease. Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998;54(5):1570-1580.
192. Fogo AB. Progression and potential regression of glomerulosclerosis. Kidney Int 2001;59(2):804-819.
193. Fagerudd JA, Groop PH, Honkanen E, Teppo AM, Gronhagen-Riska C. Urinary excretion of TGF-beta 1, PDGF-BB and fibronectin in insulindependent diabetes mellitus patients. Kidney Int Suppl 1997;63:S195-S197.
194. Ellis D, Forrest KY, Erbey J, Orchard TJ. Urinary measurement of transforming growth factor-beta and type IV collagen as new markers of renal injury: application in diabetic nephropathy. Clin Chem 1998; 44(5):950-956.
195. Sato H, Iwano M, Akai Y, Kurioka H, Kubo A, Yamaguchi T et al. Increased excretion of urinary transforming growth factor beta 1 in patients with diabetic nephropathy. Am J Nephrol 1998;18(6):490-494.
196. Hill C, Logan A, Smith C, Gronbaek H, Flyvbjerg A. Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor beta receptor expression in experimental diabetes in rats. Diabetologia 2001;44(4):495-500.
197. Taal MW, Chertow GM, Rennke HG, Gurnani A, Jiang T, Shahsafaei A et al. Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am J Physiol Renal Physiol 2001;280(2):F343-F355.
198. Campistol JM, Inigo P, Jimenez W, Lario S, Clesca PH, Oppenheimer F et al. Losartan decreases plasma levels of TGF-beta 1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999;56(2):714-719.
199. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R et al. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999;34(5):818-823.
200. Tuomilehto J, Borch-Johnsen K, Molarius A, Forsén T, Rastenyte D, Sarti C et al. Incidence of cardiovascular disease in type 1 diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia 1998;41:784-790.
201. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. Diab 2000;49(3):485-491.
202. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest 1995;96:1395-1403.
203. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999;100(11):1223-1229.
204. Clausen P, Jacobsen P, Rossing K, Jensen JS, Parving HH, Feldt-Rasmussen B. Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with Type 1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabet Med 2000;17(9):644-649.
205. Fasching P, Veitl M, Rohac M, Streli C, Schneider B, Waldhausl W et al. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81(12):4313-4317.
206. Andersen S, Schalkwijk CG, Stehouwer CD, Parving HH. Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy. Diabetes Care 2000;23(7):1031-1032.
207. Gasic S, Wagner OF, Fasching P, Ludwig C, Veitl M, Kapiotis S et al. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens 1999;12(2 Pt 1):217-222.
208. Ferri C, Desideri G, Baldoncini R, Bellini C, de Angelis C, Mazzocchi C et al. Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities. Diab 1998;47:660-667.
209. Schmidt AM, Crandall J, Hori O, Cao R, Lakatta E. Elevated plasma levels of vascular cell adhesion molecule-1 (VCAM-1) in diabetic patients with microalbuminuria: a marker of vascular dysfunction and progressive vascular disease. Br J Haematol 1996;92(3):747-750.
210. Bos H, Andersen S, Rossing P, de Zeeuw D, Parving HH, de Jong PE et al. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int 2000; 57(Suppl. 75):S-32-S-37.
211. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998;13(7):1682-1685.
212. Parving HH, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. Br Med J 1996;313:591-594.
213. Jacobsen P, Rossing K, Rossing P, Tarnow L, Mallet C, Poirier O et al. Role of an insertion/deletion polymorphism in the angiotensin converting enzyme gene on antiproteinuric effect of ACE inhibition in IDDM patients with diabetic nephropathy: an observational follow-up study. Kidney Int 1998;53:1002-1006.
214. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-1346.
215. Staessen JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 1997;15: 1579-1592.
216. Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998;41(1):47-53.
217. Kunz R, Bork JP, Fritsche L, Ringel J, Sharma AM. Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: a methodological appraisal and systematic review. J Am Soc Nephrol 1998;9:1653-1663.
218. Tarnow L, Gluud C, Parving H-H. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 1998;13:1125-1130.
219. Vleming LJ, van der Pijl JW, Lemkes HHPJ, Westendorp RGJ, Maassen JA, Daha MR et al. The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. Clin Nephrol 1999;51(3):133-140.
220. Schmidt S, Ritz E. Angiotensin I converting enzyme gene polymorphism and diabetic nephropathy in type II diabetes. Nephrol Dial Transplant 1997;12(2):37-41.
221. Yoshida H, Kuriyama S, Atsumi Y, Tomonari H, Mitarai T, Hamaguchi A et al. Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 1996;50(2):657-664.
222. Björck S, Blohmé G, Sylvén C, Mulec H. Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy. Nephrol Dial Transplant 1997;12(Suppl. 2):67-70.
223. Hadjadj S, Belloum R, Bouhanick B, Gallois Y, Guilloteau G, Chatellier G et al. Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. J Am Soc Nephrol 2001;12(3):541-549.
224. Rudberg S, Rasmussen LM, Bangstad H-J, Österby R. Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria. Diabetes Care 2000;23(4):544-548.
225. Solini A, Vestra MD, Saller A, Nosadini R, Crepaldi G, Fioretto P. The angiotensin-converting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes. Diab 2002;51(1):251-255.
226. van Essen GG, Rensma PL, de Zeeuw D, Sluiter WJ, Scheffer H, Apperloo AJ et al. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996;347: 94-95.
227. Harden PN, Geddes C, Rowe PA, McIlroy JH, Boulton-Jones M, Rogers S et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995;345:1540-1542.
228. Perna A, Ruggenenti P, Testa A, Spoto B, Benini R, Misefari V et al. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. Kidney Int 2000;57(1):274-281.
229. Jacobsen P, Rossing K, Rossing P, Tarnow L, Mallet C, Poirier O et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998;53:1002-1006.
230. Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients - findings from the EUCLID randomized controlled trial. Diab 1998;47:1507-1511.
231. Marre M, Bernadet P, Gallois Y, Savagner F, Guyenne T-T, Hallab M et al. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diab 1994;43:384-388.
232. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L et al. Lack of relationship between an insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diab 1995;44:489-494.
233. Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll HK et al. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease. Kidney Blood Press Res 1998;21(1):66-69.
234. van der Kleij FG, Navis GJ, Gansevoort RT, Heeg JE, Scheffer H, de Zeeuw D et al. ACE polymorphism does not determine short-term renal response to ACE- inhibition in proteinuric patients. Nephrol Dial Transplant 1997;12(Suppl 2):42-46.
235. Lachurie M-L, Azizi M, Guyenne T-T, Alhenc-Gelas F, Menard J. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 1995;91:2933-2942.
236. Ueda S, Elliott HL, Morton JJ, Connell JM. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension 1995;25(6):1266-1269.
237. Buikema H, Pinto YM, Rooks G, Grandjean JG, Schunkert H, van Gilst WH. The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J 1996;17(5):787-794.
238. van Dijk MA, Kroon I, Kamper AM, Boomsma F, Danser AH, Chang PC. The angiotensin-converting enzyme gene polymorphism and responses to angiotensins and bradykinin in the human forearm.J Cardiovasc Pharmacol 2000;35(3):484-490.
239. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000;405(6788):857-865.
240. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and Angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. J Am Soc Nephrol. In press.
241. Komine N, Khang S, Wead LM, Blantz RC, Gabbai FB. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 2002; 39(1):159-164.
242. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000;321(7274):1440-1444.
243. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002;25(1):95-100.
244. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002;17(6):1019-1024.
245. Hebert LA, Falkenhain ME, Nahman NS Jr, Cosio FG, O'Dorisio TM. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999;19(1):1-6.
246. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361(9352):117-124.
247. Laffel LMB, McGill JB, Gans JD. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995;99:497-504.
248. O'Donnell MJ, Rowe BR, Lawson N, Horton A, Gyde OH, Barnett AH. Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. J Hum Hypertens 1993;7(4):327-332.
249. Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care 1998;21(1):104-110.
250. The Euclid Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-1792.
251. Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Br Med J 1991;302:210-216.
252. Poulsen PL, Ebbehoj E, Nosadini R, Fioretto P, Deferrari G, Crepaldi G et al. Early ACE-i intervention in microalbuminuric patients with type 1 diabetes: effects on albumin excretion, 24 h ambulatory blood pressure, and renal function. Diabetes Metab 2001;27(2 Pt 1):123-128.
253. Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria. The European Study for the prevention of Renal disease in Type 1 Diabetes (ESPRIT). Diabetes 2001;50: 843-850.
254. Bojestig M, Karlberg BE, (Sweden) PSG. Ace-inhibition during two years did not improve U-AER in normotensive microalbuminuric IDDM patients. Diabetologia 40(Suppl. 1):A544-1997.
255. O'Hare P, Bilbous R, Mitchell T, O'Callaghan CJ, Viberti GC. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 2000;23(12):1823-1829.